Nasdaq · CIK 0001455365
CGTX COGNITION THERAPEUTICS INC
Insider trading from SEC Form 4. Last filing Dec 22, 2025. Close $0.88 on Oct 9, 2026, +47% from the 52-week low and -55% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
CGTXOct 9, 2026 · close 0.88
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at COGNITION THERAPEUTICS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Lisa Ricciardi CEO & President buy | $30k 38,851 shares | - | - |
Transactions
The last 30 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 18, 2025 | Anthony Caggiano Chief Medical Officer | AGrant or award Common Stock | +65,000 | $0.00 | $0 | 528,273 | Dec 22, 2025 |
| Dec 18, 2025 | Lisa Ricciardi CEO & President | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 1,013,666 | Dec 22, 2025 |
| Dec 18, 2025 | John Brendan Doyle Chief Financial Officer | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 455,350 | Dec 22, 2025 |
| Dec 18, 2025 | John Brendan Doyle Chief Financial Officer | FTax withholding Common Stock | -9,360 | $1.50 | $14k | 445,990 | Dec 22, 2025 |
| Dec 18, 2025 | Anthony Caggiano Chief Medical Officer | FTax withholding Common Stock | -20,280 | $1.50 | $30k | 507,993 | Dec 22, 2025 |
| Dec 18, 2025 | Lisa Ricciardi CEO & President | FTax withholding Common Stock | -23,400 | $1.50 | $35k | 990,266 | Dec 22, 2025 |
| Sep 19, 2025 | Aaron G.L. Fletcher director, owner | MOption exercise Common Stock | +7,729 | $0.84 | $6,492 | 56,229 | Sep 23, 2025 |
| Sep 19, 2025 | Aaron G.L. Fletcher director, owner | MOption exercise Stock Option (right to buy)derivative | -7,729 | $0.00 | $0 | 0 | Sep 23, 2025 |
| Jul 29, 2025 | Lisa Ricciardi CEO & President | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 962,066 | Jul 31, 2025 |
| Jul 29, 2025 | John Brendan Doyle Chief Financial Officer | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 434,710 | Jul 31, 2025 |
| Jul 29, 2025 | Anthony Caggiano Chief Medical Officer | AGrant or award Common Stock | +65,000 | $0.00 | $0 | 483,554 | Jul 31, 2025 |
| Jul 29, 2025 | Lisa Ricciardi CEO & President | FTax withholding Common Stock | -23,400 | $0.67 | $16k | 938,666 | Jul 31, 2025 |
| Jul 29, 2025 | Anthony Caggiano Chief Medical Officer | FTax withholding Common Stock | -20,281 | $0.67 | $14k | 463,273 | Jul 31, 2025 |
| Jul 29, 2025 | John Brendan Doyle Chief Financial Officer | FTax withholding Common Stock | -9,360 | $0.67 | $6,273 | 425,350 | Jul 31, 2025 |
| Jun 18, 2025 | Jack A. Khattar director | AGrant or award Common Stock | +34,000 | $0.00 | $0 | 48,500 | Jun 23, 2025 |
| Jun 18, 2025 | Brett P Monia director | AGrant or award Common Stock | +34,000 | $0.00 | $0 | 48,500 | Jun 23, 2025 |
| Jun 18, 2025 | Ellen B Richstone director | AGrant or award Common Stock | +34,000 | $0.00 | $0 | 58,500 | Jun 23, 2025 |
| Jun 18, 2025 | Peggy Wallace director | AGrant or award Common Stock | +34,000 | $0.00 | $0 | 86,461 | Jun 23, 2025 |
| Jun 18, 2025 | Leslie W. Kreis director, owner | AGrant or award Common Stockindirect: See Footnote | +34,000 | $0.00 | $0 | 48,500 | Jun 20, 2025 |
| Jun 18, 2025 | Aaron G.L. Fletcher director, owner | AGrant or award Common Stock | +34,000 | $0.00 | $0 | 48,500 | Jun 20, 2025 |
| May 1, 2025 | John Brendan Doyle Chief Financial Officer | FTax withholding Common Stock | -9,692 | $0.45 | $4,334 | 404,710 | May 2, 2025 |
| Feb 15, 2025 | John Brendan Doyle Chief Financial Officer | FTax withholding Common Stock | -1,723 | $0.59 | $1,017 | 414,402 | Feb 18, 2025 |
| Feb 15, 2025 | Anthony Caggiano Chief Medical Officer | FTax withholding Common Stock | -5,296 | $0.59 | $3,125 | 418,554 | Feb 18, 2025 |
| Feb 15, 2025 | Lisa Ricciardi CEO & President | FTax withholding Common Stock | -6,619 | $0.59 | $3,906 | 887,066 | Feb 18, 2025 |
| Feb 4, 2025 | John Brendan Doyle Chief Financial Officer | AGrant or award Common Stock | +295,000 | $0.00 | $0 | 416,125 | Feb 4, 2025 |
| Feb 3, 2025 | Anthony Caggiano Chief Medical Officer | FTax withholding Common Stock | -12,779 | $0.67 | $8,511 | 128,850 | Feb 4, 2025 |
| Jan 31, 2025 | Lisa Ricciardi CEO & President | POpen-market purchase Common Stockindirect: By Spouse | +38,851 | $0.77 | $30k | 38,851 | Feb 4, 2025 |
| Feb 4, 2025 | Anthony Caggiano Chief Medical Officer | AGrant or award Common Stock | +295,000 | $0.00 | $0 | 423,850 | Feb 4, 2025 |
| Feb 3, 2025 | Lisa Ricciardi CEO & President | FTax withholding Common Stock | -28,960 | $0.67 | $19k | 262,385 | Feb 4, 2025 |
| Feb 4, 2025 | Lisa Ricciardi CEO & President | AGrant or award Common Stock | +631,300 | $0.00 | $0 | 893,685 | Feb 4, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Anthony CaggianoChief Medical Officer
- John Brendan DoyleChief Financial Officer
- Aaron G.L. Fletcherowner, director
- Jack A. Khattarceo, president, officer, director
- Leslie W. Kreisowner, director
- Brett P Moniaceo, officer, director
- Ellen B Richstonedirector
- Lisa RicciardiCEO & President
- Peggy Wallacedirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.